Tag Archives: Alzheimer’s Disease

Europe bursts onto the biotech scene as Grifols’ Phase 2b/3 plasma replacement therapy works in Alzheimer’s patients. Buy, sell or hold?

The News: A blood plasma replacement therapy from Spanish company Grifols SA (Barcelona) reduced cognitive decline by 61% in patients with moderate Alzheimer’s disease compared with placebo, Labiotech.eu reports. The… Read more »

Atrial fibrillation increases risk of dementia by 40%, Swedish study shows. Bring on those blood thinners, say researchers.

The News: New evidence suggests that atrial fibrillation, in which the heart has an irregular beat, is linked to an increased risk of dementia. An irregular heartbeat speeds up the… Read more »

Researchers say autobiographical memory test may foretell Alzheimer’s risk. Study invokes friends, relatives and sparks uneasy self-reflection.

The News: Testing how well people remember past events in their lives could help medical professionals make early predictions about who is at risk for developing Alzheimer’s disease (AD), according… Read more »

Forget about Biogen/Eisai’s promising new drug for Alzheimer’s; Study says aggressive blood-pressure treatment with existing meds reduces dementia/AD risk.

The News: After decades of prominent failures, hope arose for a drug to slow the progression of Alzheimer’s disease (AD). After heightening expectations recently, Eisai Co. Ltd. (Tokyo) and Biogen… Read more »

Tiny Swedish biotech not taking back seat to US in Alzheimer’s race. How to buy it.

The News: BioArctic AB, based in Stockholm, said it has clinical results showing its antibody treatment that targets amyloid plaques, a hallmark of Alzheimer’s disease, can slow the disease’s progression. The trial… Read more »

Coffee drinkers stunned as new study suggests caffeine consumption worsens Alzheimer’s symptoms. Now what?

The News: Long-term consumption of caffeine would worsen the neuropsychiatric symptoms of people with Alzheimer’s disease, according to a study on mice, published in Frontiers in Pharmacology. So far, many studies… Read more »

Heath stock take it on the chin while immuno-oncology IPOs keep a coming.

1. Medical Stock Spotlight 1) Losers far outpaced winners last week with Edge Therapeutics Inc. (Nasdaq:EDGE) nosediving 93% over the week to $1.18. Up until last week, shares of Edge Thera… Read more »